Jason Bednar
Stock Analyst at Piper Sandler
(2.17)
# 2,813
Out of 4,944 analysts
180
Total ratings
38.3%
Success rate
-4.17%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SOLV Solventum | Maintains: Overweight | $87 → $94 | $74.38 | +26.38% | 7 | Aug 8, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $185 → $200 | $195.96 | +2.06% | 10 | Aug 8, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $155.97 | +34.64% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $21.56 | -11.87% | 13 | Aug 1, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $110 → $105 | $86.15 | +21.88% | 13 | Jul 31, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $250 → $190 | $145.74 | +30.37% | 31 | Jul 31, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.54 | +62.34% | 12 | Jul 31, 2025 | |
| NVCR NovoCure | Reiterates: Overweight | $34 | $11.62 | +192.60% | 11 | Jun 27, 2025 | |
| COO The Cooper Companies | Reiterates: Overweight | $115 → $105 | $74.27 | +41.38% | 13 | May 30, 2025 | |
| KRMD KORU Medical Systems | Maintains: Neutral | $4.5 → $3.5 | $4.30 | -18.60% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $13.85 | +15.52% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $68.99 | +11.61% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $15.72 | -17.30% | 2 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $1.35 | +233.33% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $247.07 | +7.26% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $2.75 | +118.18% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.42 | +104.68% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $2.45 | +716.33% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $482.35 | -22.88% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $75.33 | +26.11% | 1 | Apr 19, 2023 |
Solventum
Aug 8, 2025
Maintains: Overweight
Price Target: $87 → $94
Current: $74.38
Upside: +26.38%
Becton, Dickinson and Company
Aug 8, 2025
Maintains: Neutral
Price Target: $185 → $200
Current: $195.96
Upside: +2.06%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $155.97
Upside: +34.64%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $21.56
Upside: -11.87%
Merit Medical Systems
Jul 31, 2025
Maintains: Overweight
Price Target: $110 → $105
Current: $86.15
Upside: +21.88%
Align Technology
Jul 31, 2025
Maintains: Overweight
Price Target: $250 → $190
Current: $145.74
Upside: +30.37%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.54
Upside: +62.34%
NovoCure
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $11.62
Upside: +192.60%
The Cooper Companies
May 30, 2025
Reiterates: Overweight
Price Target: $115 → $105
Current: $74.27
Upside: +41.38%
KORU Medical Systems
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $4.30
Upside: -18.60%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $13.85
Upside: +15.52%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $68.99
Upside: +11.61%
Apr 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $15.72
Upside: -17.30%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.35
Upside: +233.33%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $247.07
Upside: +7.26%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $2.75
Upside: +118.18%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.42
Upside: +104.68%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $2.45
Upside: +716.33%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $482.35
Upside: -22.88%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $75.33
Upside: +26.11%